WO1993017673A1 - Analgesique a liberation controlee - Google Patents

Analgesique a liberation controlee Download PDF

Info

Publication number
WO1993017673A1
WO1993017673A1 PCT/AU1993/000088 AU9300088W WO9317673A1 WO 1993017673 A1 WO1993017673 A1 WO 1993017673A1 AU 9300088 W AU9300088 W AU 9300088W WO 9317673 A1 WO9317673 A1 WO 9317673A1
Authority
WO
WIPO (PCT)
Prior art keywords
analgesic
composition according
paracetamol
release
dose
Prior art date
Application number
PCT/AU1993/000088
Other languages
English (en)
Inventor
Ralph Anthony Papandrea
Richard Edward Thomas
Original Assignee
Top Gold Pty., Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Top Gold Pty., Limited filed Critical Top Gold Pty., Limited
Priority to AU36229/93A priority Critical patent/AU3622993A/en
Publication of WO1993017673A1 publication Critical patent/WO1993017673A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine

Definitions

  • This invention relates to the preparation of analgesics in sustained release form. More particularly, it relates to the preparation of non-opioid analgesic agents in a sustained release form.
  • analgesic encompasses a broad range of pharmaceutical compounds that fall into three main categories: opioid (or narcotic) analgesics; non-steroidal anti-inflammatory agents (NSAIDs) ; and non-opioid analgesics. Included among the opioids are the opium alkaloids and their semi-synthetic derivatives (such as meperidine and methadone) that have somewhat different structures but similar effects, and the "opiopeptins" (such as ⁇ -endorphin and the enkephalins) . Opioid analgesics produce pain relief and sedation by way of a diverse range of biochemical pathways involving one or more classes of opioid receptors.
  • analgesics that fall within this class are morphine and codeine.
  • Opioid analgesics have traditionally been referred to as 'narcotic analgesics' to distinguish them from the antipyretic (or coal tar) analgesics such as aspirin, phenacetin and paracetamol (acetaminophen) .
  • Aspirin is now classified as an NSAID.
  • NSAIDs encompass a broad range of pharmaceutical drugs which share the capacity to suppress the signs and symptoms of inflammation. It is this mode of action which makes these drugs particularly useful in the management of disorders in which pain is related to the intensity of the inflammatory process.
  • NSAIDs are widely used for the treatment of inflammatory disorders of muscular, skeletal, vascular and connective tissues, including such conditions as arthritis, bursitis, postpartum states and dental pain, to mention a few. These drugs are heterogenous in chemical structure but have in common the ability to inhibit prostaglandin synthesis.
  • a well-known example of the analgesics which fall within this class is aspirin.
  • Non-opioid, non-NSAID, analgesics encompass a small range of pharmaceutical compounds of which phenacetin and paracetamol (acetaminophen) are well-known examples. These pharmaceuticals are particularly useful for the treatment of mild to moderate pain where an anti-inflammatory effect is not necessary. Their use includes the treatment of headaches, myalgia, postpartum pain and other medical conditions that require mild pain relief.
  • paracetamol acetaminophen
  • aspirin a non-opioid analgesic
  • paracetamol acetaminophen
  • aspirin a non-opioid analgesic
  • paracetamol can be used for treating patients with a history of peptic ulcers or patients where bronchospasm is precipitated by NSAIDs such as aspirin.
  • analgesics in general, depends on the type and intensity of the pain and the particular analgesic agent used. For example, 500-1000 mg of paracetamol is normally used to combat mild pain and fever in adult humans. When administered orally this drug has a half-life of approximately two to three hours in the body. Accordingly, it has hitherto been practiced to re-administer the drug at intervals of 4 to 6 hours to maintain an effective concentration.
  • the present invention relates to a composition
  • a composition comprising at least one analgesic in a dose form adapted for sustained release and in a concentration selected to provide an analgesically effective dose at a substantially constant dose rate over at least 8 hours.
  • the analgesic which is adapted for substained release can be selected from the group consisting of opioid analgesics, non-steroidal anti-inflammatory analgesic and non-opioid analgesics.
  • the analgesic is a non-opioid analgesic such as paracetamol.
  • Analgesics may also be adapted in a substained release form with other analgesics or medications such as doxylamine.
  • a typical combination used in the present invention consists of paracetamol and codeine or paracetamol, codeine and doxylamine.
  • paracetamol is selected as the analgesic. Hitherto, it has been usual to administer paracetamol in dose units of up to 500 mg per unit and to administer up to two such dose units (1000 mg total dose) each 4 hours.
  • paracetamol is provided in a sustained release form which provides a substantially constant dose rate of from 150 - 400 mg/hr sustained for at least 8 hours.
  • a total dose of, for example, from 1200 to 3200 mg is administered by means adapted for constant rate release over 8 hours.
  • the 1200 to 3200 mg can be in one dosage unit or can be in two dosage units suitable to be administered together and each containing from 600 to 1600 mg adapted for release over 8 or more hours, and so forth.
  • the constant dose rate is from 200 to 300 mg/hr for at least 8 hours and more preferably about 240 to 260 mg/hr.
  • the constant dose rate in mg/hr for other non-opioid analgesics to give an analgesically effective rate may be greater or less than 150 - 400 mg/hr but will in general be about 1.5 to 3 times as great as the amount normally previously administered without sustained release.
  • the dosage form which is adapted for substained release preferably releases the analgesic at a substantially uniform rate over a period of at least 8 hours and preferably from 8 to 12 hours or more preferably over a period of from 8 to 24 hours.
  • the period of substained release is dependent on the analgesic used and the requirement of the patient. Any suitable dosage form providing release of the analgesic over a long period and preferably at a uniform rate of release may be used.
  • the present invention further relates to a composition
  • a composition comprising at least one analgesic having a dose unit in the range of from 500 mg to 1500 mg and in a dosage form adapted for substained release wherein said composition further comprises an analgesic adapted for rapid release.
  • rapid release means that the analgesic is released quickly for example in less than 1 hour, more preferably in less than 30 minutes.
  • analgesics in a dose form adapted for rapid release can be selected from the group consisting of opioid analgesics, non-steroidal anti-inflammatory analgesic and non-opioid analgesic.
  • the analgesic is a non-opioid analgesic such as paracetamol.
  • Analgesics in a sustained release form may be combined with other analgesics or medications such as doxylamine.
  • a typical combination used in the present invention consists of paracetamol and codeine or paracetamol, codeine and doxylamine.
  • the present invention also relates to a method for avoiding the pain rebound effect comprising administering an analgesically effective amount of a composition comprising at least one analgesic from a dosage form adapted for substained release at a constant rate over at least 8 hours.
  • a particular advantage resulting from the present invention is that analgesics in a sustained release form remain in the body and, more particularly, the blood, for longer periods of time, and taper off gradually as the sustained-releasing means wears out. This is particularly advantageous as it allows natural endogenous analgesic substances in the patient's body to re-assert their action, thereby reducing the so-called pain "rebound" effect which is seen with non-sustained release analgesic preparations.
  • Methods of applying a sustained release composition broadly fall into three categories namely transdermal, oral and implantation means.
  • Transdermal administration of a drug to a patient may take place in a number of ways.
  • a typical example is the use of pharmaceutical patches that contain drugs for transdermal administration.
  • Oral sustained release formulations of drugs include incorporation in slow release reservoirs or by any other means known in the art.
  • Sustained release by implantation of a drug generally occurs at the sub-dermal level where the drug to be released is packaged in a slow release device.
  • methods of sustaining the release of a product are well-known in the art and, as such, any recognized means of slowing the release of an analgesic may be used in the present invention.
  • Preferred formulations include microcapsules coated with agents such as ethylcellulose incorporating waxes such as paraffin wax, with our without an overlay of an enteric coating such as cellulose acetate.
  • agents such as ethylcellulose incorporating waxes such as paraffin wax
  • enteric coating such as cellulose acetate.
  • Another preferred approach is the preparation of microspheres. Although the latter have usually achieved an incorporation level of no better than 50%, incorporation of 80-90% can now be achieved. Microspheres can also be formulated to provide a burst effect in which a portion of the drug is released quickly and the remainder over a prolonged period.
  • oral means for sustaining the release of an analgesic may generally be categorized in two classes namely encapsulation or in tablet form.
  • the first approach is to combine a physical mixture or a form of granulation of the active ingredients and a suitable hydrophilic polymer.
  • the combination of powder can then be dispensed in a conventional gelatin capsule.
  • the same approach may be employed, with only a few modifications in the formulation of tablets.
  • the second approach is to produce suitable particles of the active ingredient(s) and to deposit a polymeric coating on them.
  • the coating material may be chosen such that an enteric effect is obtained or that release will be more uniform throughout the whole of the gastrointestinal tract. This technique is generally referred to as microcapsule formation.
  • Microspheres are solid particles of a matrix material through which the active ingredients are uniformly or non-uniformly dispersed. Uniform distribution is technically easier to attain, but calculated non-uniform distribution may lead to better attainment of zero-order release.
  • a variety of synthetic or natural materials can be employed as the matrix.
  • APPROACH 1 (POWDER MIXTURE (GRANULATION) WITH -?.. HYDROPHILIC POLYMER)
  • This approach employs a physical mixture (or some form of granulation) of the active ingredients with a suitable hydrophilic polymer.
  • the combination of powders is dispensed in a conventional gelatin capsule.
  • the expected mechanism(s) of release is diffusional release of the relatively water-soluble active ingredients through the hydrated and presumably swollen polymer matrix, and drug release due to biodegradation of the matrix.
  • APPROACH 2 (MICROCAPSULE FORMATION)
  • microcapsules are well known in the art. Basically, the techniques involve the deposition of a polymer coating onto core particles of drug.
  • the release characteristics time to release, pH dependency etc
  • the thickness of the coating applied Accurate control of the release pattern usually depends critically on the integrity of the polymer coating.
  • Pan-coating is a simple means of depositing the coating, but requires large (at least 0.5 mm diameter) spherical particles to achieve a good rolling action in the pan and to avoid aggregation. This can be achieved by the attrition of large particles in suitable mechanical equipment
  • one particular technique employs spheronization in which 20-40 mesh particles of paracetamol are sprayed with alcoholic PVP, dusted with fine powdered drug and rolled dry in a stream of cold air. The process is repeated until spherical particles of the required size and shape are obtained.
  • the cores can be polymer-coated to yield sustained release.
  • the process has the advantage that the cores have a very high content of active ingredient, especially compared to techniques in which granules are prepared using conventional binders such as microcrystalline cellulose or carboxy-methylcellulose.
  • An alternative method may involve coating spherical cores with ethylcellulose. This method may be accomplished by dissolving the polymer in cyclohexane at 80-81°C, dispersing the cores in a vigorously stirred solution and then gradually cooling the liquid. The polymer separates as a liquid coacervate and deposits onto the cores which are prevented from aggregating by stirring. At 20-25°C, the microcapsules are filtered and dried. The microspheres can be made more hydrophobic by incorporating waxes (e.g. paraffin) in the cyclohexane with the ethylcellulose.
  • waxes e.g. paraffin
  • Paracetamol cores coated with ethylcellulose can also be coated with cellulose acetate phthalate as an enteric coat on a non-disintegrating particle. Cores coated in this way will release very slowly in an acidic environment and faster (but relatively constantly) in an alkaline medium.
  • APPROACH 3 (MICROSPHERE FORMATION)
  • microspheres ladened with active drug is well known in the art.
  • actives can be combined with waxy monoglycerides, in poly (hydroxy butyric acid) and in gelatin to name a few means of forming microspheres.
  • An alternative approach is to produce 30 mesh polystyrene beads which can be expanded and made more porous by soaking in n-pentane prior to boiling in water. The beads are able to take up about 20% by weight of paracetamol by soaking in alcoholic solution. When administered to a patient about 65% of the load is released over a relatively short period of time (e.g. 30 to 60 mins) and the remainder over a 24 hour period. Paracetamol may be incorporated in egg albumin microspheres.
  • the albumin matrix may be hardened by employing both thermal denaturation and cross-linking with glutanaldehyde.
  • the microspheres produced might then be pan-coated with polymethacrylate to prolong the release of the active without compromising the bioavailability of paracetamol.
  • Paracetamol might also be entrapped in microspheres by the drug suspending in a viscous solution of sodium alginate and extruding the product into a solution of calcium ions to produce spherical beads of calcium alginate which contain the entrapped drug. The beads may then be collected and dried to form a delivery system which results in prolonged release.
  • a similar technique utilizes entrapment of active drugs in chitosan beads gelled with sodium tripolyphosphate. Such methods readily allow the incorporation of 80-90% w/w of drug in the beads and result in prolonged release of the drug. The use of such systems can prolong drug release for about 6 hours in an acidic medium.
  • Microspheres and Microcapsules would not desirably be presented as tablets since compression would result in crushing of the sphere or cracking of the rate-controlling membrane of a microcapsule. If compression is used to decrease the volume of the active ingredient(s) by powder densification then it is important that any hydrophilic polymer combined with the active is compressible. Further, the formulation may require the addition of binding, lubricating and flow-enhancing excipients.
  • a direct compression vehicle e.g. calcium phosphate dehydrate or hydroxyapatite
  • each adult contains from 600 mg to 1,600 mg of paracetamol (preferably 1000 mg) so that the total dose administered with 2 dose units is 1200 to 3200 mg of paracetamol.
  • Each dose unit is adapted to release the paracetamol at 75 - 200 mg/hr over 8 hours, thus providing a total administered dose rate of 150 - 400 mg/hr for 8 hours.
  • the dose units are adapted to provide 100 - 150 mg/hr and more preferably 125 mg/hr per dose unit. 2 dose units taken together then provide around 200 - 300 mg/hr of paracetamol per hour and preferably 250 mg/hr for 8 hours.
  • the invention described is suitable for treating a wide range of pain conditions but is particularly suited for chronic pain such as that associated with osteoarthritis and similar disorders of the joints or muscles including chronic tension headache. It may also be used alone, or in association with other analgesic therapy, in the treatment of malignant disorders or where other chronic analgesic therapy is contraindicated. In all these cases, pain rebound can be a problem when short-acting analgesic formulations are used.
  • two sustained-release paracetamol dose units each containing 750 - 1000 mg (alone or admixed with other actives) , are administered twice daily. Because of the low incidence of adverse effects to therapeutic doses of paracetamol, the dosage regimen described above can, in most cases, be used for prolonged periods.
  • formulations containing analgesic compounds in sustained release forms may be administered to any mammal in need thereof.
  • the dosage administered will depend on the analgesic and the mammal to which a formulation is administered.
  • Formulations of sustained release analgesics should be prepared according to recognised art and dosage levels.

Abstract

L'invention concerne une composition comprenant au moins un analgésique, de préférence le paracétamol, dans une forme galénique à libération contrôlée assurant une concentration choisie suffisante pour avoir un effet analgésique. La libération de l'analgésique se fait à une vitesse sensiblement constante pendant au moins 8 heures. La vitesse de libération du paracétamol est de préférence de 150 - 400 mg/heure.
PCT/AU1993/000088 1992-03-03 1993-03-03 Analgesique a liberation controlee WO1993017673A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36229/93A AU3622993A (en) 1992-03-03 1993-03-03 Sustained release analgesics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL116792 1992-03-03
AUPL1167 1992-03-03

Publications (1)

Publication Number Publication Date
WO1993017673A1 true WO1993017673A1 (fr) 1993-09-16

Family

ID=3776018

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1993/000088 WO1993017673A1 (fr) 1992-03-03 1993-03-03 Analgesique a liberation controlee

Country Status (1)

Country Link
WO (1) WO1993017673A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004780A2 (fr) * 1995-08-02 1997-02-13 Virginia Commonwealth University Composition medicamenteuse servant a soulager la douleur et methode de soulagement de la douleur
AU678859B2 (en) * 1993-11-23 1997-06-12 Euro-Celtique S.A. Immediate release tablet cores of insoluble drugs having sustained release coating
GB2310601A (en) * 1996-02-27 1997-09-03 Perrigo L Co Delayed release coated paracetamol particles
WO1998017268A2 (fr) * 1996-10-24 1998-04-30 Algos Pharmaceutical Corporation Procede destine a soulager des douleurs par la combinaison de tramadol et d'un antagoniste de nmda
EP0898961A1 (fr) * 1997-08-27 1999-03-03 Herta-Maria Dr. Sahlender Composition pharmaceutique pour améliorer la thérapie de la douleur aigüe, postoperatoire ou chronique
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US8808737B2 (en) 2007-06-21 2014-08-19 Endo Pharmaceuticals Inc. Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US9974752B2 (en) 2014-10-31 2018-05-22 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU522080B2 (en) * 1978-02-17 1982-05-13 Metallgesellschaft Aktiengesellschaft Hydrogenation of shale oil
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
GB2190287A (en) * 1986-05-14 1987-11-18 Birex Res & Dev Ltd Oral ketoprofen formulation
EP0255002A1 (fr) * 1986-07-23 1988-02-03 ALFA WASSERMANN S.p.A. Formulations pharmaceutiques à libération programmée contenant des agents antiphlogistiques
EP0264989A1 (fr) * 1986-10-01 1988-04-27 PROTER S.p.A. Formes galéniques par voie orale à libération prolongée de dérivés de rhein
US4803079A (en) * 1983-06-14 1989-02-07 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
EP0309157A1 (fr) * 1987-09-24 1989-03-29 American Home Products Corporation Etodolac à libération soutenue
EP0324981A1 (fr) * 1988-01-18 1989-07-26 ALFA WASSERMANN S.p.A. Formulations galéniques à libération programmée
EP0351580A2 (fr) * 1988-07-18 1990-01-24 Shionogi Seiyaku Kabushiki Kaisha Préparation à libération retardée et leur procédé de fabrication
EP0396425A2 (fr) * 1989-05-05 1990-11-07 Kv Pharmaceutical Company Formulations pharmaceutiques à libération prolongée
EP0438249A1 (fr) * 1990-01-15 1991-07-24 Elan Corporation Plc Formule de naproxen à absorption controlée pour l'administration une fois par jour
AU8186291A (en) * 1990-07-13 1992-02-04 Farcon Ag A controlled-release pharmaceutical composition for the oral use containing non steroidal anti-inflammatory drugs
EP0263083B1 (fr) * 1986-09-30 1993-06-23 Roberto Valducci Membrane d'enrobage et compositions préparées avec celle-ci

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU522080B2 (en) * 1978-02-17 1982-05-13 Metallgesellschaft Aktiengesellschaft Hydrogenation of shale oil
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
US4803079A (en) * 1983-06-14 1989-02-07 Syntex (U.S.A.) Inc. Controlled release naproxen and naproxen sodium tablets
GB2190287A (en) * 1986-05-14 1987-11-18 Birex Res & Dev Ltd Oral ketoprofen formulation
EP0255002A1 (fr) * 1986-07-23 1988-02-03 ALFA WASSERMANN S.p.A. Formulations pharmaceutiques à libération programmée contenant des agents antiphlogistiques
EP0263083B1 (fr) * 1986-09-30 1993-06-23 Roberto Valducci Membrane d'enrobage et compositions préparées avec celle-ci
EP0264989A1 (fr) * 1986-10-01 1988-04-27 PROTER S.p.A. Formes galéniques par voie orale à libération prolongée de dérivés de rhein
EP0309157A1 (fr) * 1987-09-24 1989-03-29 American Home Products Corporation Etodolac à libération soutenue
EP0324981A1 (fr) * 1988-01-18 1989-07-26 ALFA WASSERMANN S.p.A. Formulations galéniques à libération programmée
EP0351580A2 (fr) * 1988-07-18 1990-01-24 Shionogi Seiyaku Kabushiki Kaisha Préparation à libération retardée et leur procédé de fabrication
EP0396425A2 (fr) * 1989-05-05 1990-11-07 Kv Pharmaceutical Company Formulations pharmaceutiques à libération prolongée
EP0438249A1 (fr) * 1990-01-15 1991-07-24 Elan Corporation Plc Formule de naproxen à absorption controlée pour l'administration une fois par jour
AU8186291A (en) * 1990-07-13 1992-02-04 Farcon Ag A controlled-release pharmaceutical composition for the oral use containing non steroidal anti-inflammatory drugs

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678859B2 (en) * 1993-11-23 1997-06-12 Euro-Celtique S.A. Immediate release tablet cores of insoluble drugs having sustained release coating
WO1997004780A3 (fr) * 1995-08-02 1997-03-27 Univ Virginia Commonwealth Composition medicamenteuse servant a soulager la douleur et methode de soulagement de la douleur
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
WO1997004780A2 (fr) * 1995-08-02 1997-02-13 Virginia Commonwealth University Composition medicamenteuse servant a soulager la douleur et methode de soulagement de la douleur
US6126969A (en) * 1996-02-27 2000-10-03 L. Perrigo Company Immediate release/sustained release compressed tablets
GB2310601A (en) * 1996-02-27 1997-09-03 Perrigo L Co Delayed release coated paracetamol particles
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
GB2310601B (en) * 1996-02-27 1999-12-22 Perrigo L Co Paracetamol sustained-release formulation
WO1998017268A2 (fr) * 1996-10-24 1998-04-30 Algos Pharmaceutical Corporation Procede destine a soulager des douleurs par la combinaison de tramadol et d'un antagoniste de nmda
WO1998017268A3 (fr) * 1996-10-24 1998-06-25 Algos Pharm Corp Procede destine a soulager des douleurs par la combinaison de tramadol et d'un antagoniste de nmda
US5919826A (en) * 1996-10-24 1999-07-06 Algos Pharmaceutical Corporation Method of alleviating pain
EP0898961A1 (fr) * 1997-08-27 1999-03-03 Herta-Maria Dr. Sahlender Composition pharmaceutique pour améliorer la thérapie de la douleur aigüe, postoperatoire ou chronique
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US9820982B2 (en) 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US8808737B2 (en) 2007-06-21 2014-08-19 Endo Pharmaceuticals Inc. Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
US9789103B2 (en) 2007-06-21 2017-10-17 Endo Pharmaceuticals Inc. Method of treating pain utilizing controlled release oxymorphone pharmaceutical compositions and instruction on dosing for renal impairment
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US10507186B2 (en) 2014-10-31 2019-12-17 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10111839B2 (en) 2014-10-31 2018-10-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10292939B2 (en) 2014-10-31 2019-05-21 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10292938B2 (en) 2014-10-31 2019-05-21 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10449159B2 (en) 2014-10-31 2019-10-22 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10500162B2 (en) 2014-10-31 2019-12-10 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US9974752B2 (en) 2014-10-31 2018-05-22 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10512612B2 (en) 2014-10-31 2019-12-24 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10512613B2 (en) 2014-10-31 2019-12-24 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10568841B2 (en) 2014-10-31 2020-02-25 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10688060B2 (en) 2014-10-31 2020-06-23 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US11896722B2 (en) 2014-10-31 2024-02-13 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Similar Documents

Publication Publication Date Title
US5026559A (en) Sustained-release pharmaceutical preparation
DE19901687B4 (de) Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
US5997905A (en) Preparation of pharmaceutically active particles
EP0938316A2 (fr) Composition galenique contenant des antagonistes des opioides
JP2003508422A (ja) 放出制御ペレット製剤
SK30396A3 (en) Beads, method for producing them and a pharmaceutical preparation containing the same
AU778151B2 (en) Oral administration form for administering a fixed tramadol and diclofenac combination
US20090011034A1 (en) Sustained release micropellets and process for producing the same
WO1992001446A1 (fr) Formulations a liberation entretenue
JP2000212068A (ja) 薬学的有効物質９０重量％まで含有するペレットの製造方法。
JP2000510488A (ja) 改良投薬ユニット
CN102046155A (zh) 包含多颗粒的具有双重释放特性的固体口服剂型
WO1993017673A1 (fr) Analgesique a liberation controlee
Obitte et al. The use of a pH-dependent and Non pH-dependent natural hydrophobic biopolymer (Landolphia owariensis latex) as capsule coating agents in in vitro controlled release of metronidazole for possible colon targeted delivery
EP1109535B1 (fr) Acetaminophene a liberation prolongee
EP1109540B1 (fr) Acetaminophene a liberation prolongee
AU1010700A (en) Analgesic with Controlled Active Substance Release
US5674529A (en) Alkalinizing potassium salt controlled release preparations
KR20000036039A (ko) 방출 조절된 [Ｒ-(Ｚ)]-α-(메톡시이미노)-α-(1-아자비시클
KR20050047507A (ko) 구형 펠렛 제제
FI101855B (fi) Menetelmä asetatsolamidia jatkuvasti vapauttavan asetatsolamidivalmist een valmistamiseksi
AU3622993A (en) Sustained release analgesics
Mahendra Babu Formulation and Evaluation of Epalrestat Microspheres
Naseed Design and evaluation of ketorolac tromethamine sustained release matrix tablets
ITMI941408A1 (it) Formulazione a rilascio modificato per la somministrazione di farmaci antiinfiammatori non steroidei

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA